SI0968208T1 - Spojine kinolina in kinazolina, uporabne za terapijo, zlasti pri zdravljenju benigne hiperplazije prostate - Google Patents

Spojine kinolina in kinazolina, uporabne za terapijo, zlasti pri zdravljenju benigne hiperplazije prostate

Info

Publication number
SI0968208T1
SI0968208T1 SI9830477T SI9830477T SI0968208T1 SI 0968208 T1 SI0968208 T1 SI 0968208T1 SI 9830477 T SI9830477 T SI 9830477T SI 9830477 T SI9830477 T SI 9830477T SI 0968208 T1 SI0968208 T1 SI 0968208T1
Authority
SI
Slovenia
Prior art keywords
quinoline
therapy
treatment
compounds useful
benign prostatic
Prior art date
Application number
SI9830477T
Other languages
English (en)
Inventor
David Nathan Abraham Pfizer Central Res. Fox
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SI0968208T1 publication Critical patent/SI0968208T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
SI9830477T 1997-01-11 1998-01-06 Spojine kinolina in kinazolina, uporabne za terapijo, zlasti pri zdravljenju benigne hiperplazije prostate SI0968208T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9700504.5A GB9700504D0 (en) 1997-01-11 1997-01-11 Pharmaceutical compounds
EP98904058A EP0968208B1 (en) 1997-01-11 1998-01-06 Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
PCT/EP1998/000143 WO1998030560A1 (en) 1997-01-11 1998-01-06 Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia

Publications (1)

Publication Number Publication Date
SI0968208T1 true SI0968208T1 (sl) 2003-10-31

Family

ID=10805838

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830477T SI0968208T1 (sl) 1997-01-11 1998-01-06 Spojine kinolina in kinazolina, uporabne za terapijo, zlasti pri zdravljenju benigne hiperplazije prostate

Country Status (45)

Country Link
US (4) US6169093B1 (sl)
EP (1) EP0968208B1 (sl)
JP (1) JP3357677B2 (sl)
KR (1) KR100347472B1 (sl)
CN (2) CN1191249C (sl)
AP (1) AP819A (sl)
AR (1) AR010396A1 (sl)
AT (1) ATE242238T1 (sl)
AU (1) AU724990B2 (sl)
BG (1) BG63918B1 (sl)
BR (1) BR9807068A (sl)
CA (1) CA2277473C (sl)
CZ (1) CZ295580B6 (sl)
DE (1) DE69815313T2 (sl)
DK (1) DK0968208T3 (sl)
DZ (1) DZ2394A1 (sl)
EA (1) EA002851B1 (sl)
ES (1) ES2198695T3 (sl)
GB (1) GB9700504D0 (sl)
HK (2) HK1025327A1 (sl)
HN (1) HN1998000002A (sl)
HR (1) HRP980010B1 (sl)
HU (1) HUP0000942A3 (sl)
ID (1) ID21863A (sl)
IL (1) IL130762A (sl)
IS (1) IS2012B (sl)
MA (1) MA26465A1 (sl)
MY (1) MY119623A (sl)
NO (1) NO318609B1 (sl)
NZ (1) NZ336302A (sl)
OA (1) OA11074A (sl)
PA (1) PA8444301A1 (sl)
PE (1) PE44499A1 (sl)
PL (1) PL334678A1 (sl)
PT (1) PT968208E (sl)
SA (1) SA97180705B1 (sl)
SI (1) SI0968208T1 (sl)
SK (1) SK284779B6 (sl)
TN (1) TNSN98004A1 (sl)
TR (1) TR199901604T2 (sl)
TW (1) TW444013B (sl)
UA (1) UA62945C2 (sl)
WO (1) WO1998030560A1 (sl)
YU (1) YU31699A (sl)
ZA (1) ZA98166B (sl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
KR100496089B1 (ko) * 2000-03-03 2005-06-17 화이자 인코포레이티드 4-아미노-6,7-디메톡시-2-(5-메탄설폰아미도-1,2,3,4-테트라하이드로이소퀴놀-2-일)-5-(2-피리딜)퀴나졸린 메실레이트및 다형체
CN1308324C (zh) 2000-08-31 2007-04-04 弗·哈夫曼-拉罗切有限公司 作为α-1肾上腺素能拮抗剂的喹唑啉衍生物
JP4031363B2 (ja) * 2001-01-02 2008-01-09 エフ.ホフマン−ラ ロシュ アーゲー α−1A/Bアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0112061D0 (en) * 2001-05-18 2001-07-11 Pfizer Ltd Process for the production of quinazolines
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
MXPA05002004A (es) 2002-09-26 2005-04-28 Pfizer Derivados de pirazol.
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
WO2005005397A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag 5-substituted quinazolinone derivatives
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
DK2392564T3 (da) * 2003-09-26 2014-01-13 Exelixis Inc c-Met-modulatorer og anvendelsesfremgangsmåder
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
GEP20084550B (en) 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
WO2008084493A2 (en) * 2007-01-09 2008-07-17 Unichem Laboratories Limited A novel process for the preparation of 2-halo-4-aminoquinazolines
JP2009126784A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc 2−ヨード−3,4−ジメトキシベンゾニトリルの製造方法。
JP2009126785A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc 2−ヨード−3,4−ジメトキシベンゾニトリルの製造方法
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
SG11201607973XA (en) 2014-03-24 2016-11-29 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875506A (en) * 1907-03-19 1907-12-31 Berry H Collins Guiding attachment for penholders.
GB1390014A (en) * 1971-05-07 1975-04-09 Koninklijke Pharma Fab Nv Process for the preparation of carbocyclic fused pyrimidine derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4098788A (en) * 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
US4656174A (en) 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
GB8506174D0 (en) 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
IT1270993B (it) 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
NZ325248A (en) 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
HRP980010B1 (en) 2002-06-30
OA11074A (en) 2002-03-13
KR20000070022A (ko) 2000-11-25
NO993396L (no) 1999-07-09
ES2198695T3 (es) 2004-02-01
CZ9902436A3 (cs) 2000-10-11
EP0968208B1 (en) 2003-06-04
CN1243513A (zh) 2000-02-02
DK0968208T3 (da) 2003-07-28
WO1998030560A1 (en) 1998-07-16
AP9801175A0 (en) 1998-01-31
DZ2394A1 (fr) 2003-06-04
DE69815313D1 (de) 2003-07-10
PE44499A1 (es) 1999-05-06
EA002851B1 (ru) 2002-10-31
TR199901604T2 (xx) 1999-12-21
ID21863A (id) 1999-08-05
TW444013B (en) 2001-07-01
AU724990B2 (en) 2000-10-05
IS5093A (is) 1999-06-25
BG103560A (en) 2000-06-30
MY119623A (en) 2005-06-30
HK1054389A1 (en) 2003-11-28
MA26465A1 (fr) 2004-12-20
NO318609B1 (no) 2005-04-18
US20020040028A1 (en) 2002-04-04
US6653302B2 (en) 2003-11-25
US6521629B2 (en) 2003-02-18
CN1191249C (zh) 2005-03-02
NO993396D0 (no) 1999-07-09
ATE242238T1 (de) 2003-06-15
CA2277473A1 (en) 1998-07-16
JP2000507966A (ja) 2000-06-27
PA8444301A1 (es) 2000-05-24
SK284779B6 (sk) 2005-11-03
HK1025327A1 (en) 2000-11-10
JP3357677B2 (ja) 2002-12-16
PL334678A1 (en) 2000-03-13
IL130762A0 (en) 2001-01-28
CN1403453A (zh) 2003-03-19
CZ295580B6 (cs) 2005-08-17
CA2277473C (en) 2003-08-12
TNSN98004A1 (fr) 2005-03-15
NZ336302A (en) 2000-08-25
AU6208898A (en) 1998-08-03
US6365599B1 (en) 2002-04-02
HUP0000942A2 (hu) 2001-04-28
KR100347472B1 (ko) 2002-08-07
CN1093858C (zh) 2002-11-06
HN1998000002A (es) 1999-01-08
IL130762A (en) 2005-12-18
HRP980010A2 (en) 1998-10-31
AP819A (en) 2000-04-03
UA62945C2 (en) 2004-01-15
YU31699A (sh) 2001-07-10
EA199900531A1 (ru) 2000-02-28
EP0968208A1 (en) 2000-01-05
US6169093B1 (en) 2001-01-02
HUP0000942A3 (en) 2002-06-28
US20030130259A1 (en) 2003-07-10
SA97180705B1 (ar) 2005-12-26
AR010396A1 (es) 2000-06-07
SK90799A3 (en) 2001-03-12
IS2012B (is) 2005-05-13
ZA98166B (en) 1999-07-09
BR9807068A (pt) 2000-05-02
PT968208E (pt) 2003-09-30
HK1054389B (zh) 2005-10-14
BG63918B1 (bg) 2003-06-30
DE69815313T2 (de) 2003-12-11
GB9700504D0 (en) 1997-02-26

Similar Documents

Publication Publication Date Title
SI0968208T1 (sl) Spojine kinolina in kinazolina, uporabne za terapijo, zlasti pri zdravljenju benigne hiperplazije prostate
ZA9610784B (en) Quinoline and quinazoline compounds useful in therapy.
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
AU1657097A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
EP0855910A4 (en) CONJUGATES USEFUL FOR TREATING BENIN PROSTATIC ADENOMA
ZA983968B (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia.
ZA982819B (en) Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
HK1030776A1 (en) Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
AU6570998A (en) Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
ZA991319B (en) Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
EP1140906A4 (en) IMIDAZOLONES AND THEIR USE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND OTHER DISORDERS
EP0748627A3 (en) Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
EP1435913A4 (en) METHOD OF TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER BENCH PROSTATIC PATHOLOGIES
GB9810895D0 (en) Combination therapy for the treatment of benign prostatic hyperplasia
AU2003204320A1 (en) Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
GB9602903D0 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
AU2002300904A1 (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
SI0925069T1 (sl) Uporaba Cetrorelix-a za zdravljenje benigne hipertrofije prostate in prostatnega raka
ZA988293B (en) Compositions and methods for the treatment of tumor.